Semaglutide for Sale: Where to Buy It Legally, What to Avoid, and How Pricing Actually Works

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide is a prescription-only medication in the United States; no legitimate seller will dispense it without a provider evaluation and prescription
• Brand-name semaglutide (Ozempic, Wegovy, Rybelsus) costs $900 to $1,350 per month without insurance; compounded semaglutide from licensed U.S. pharmacies typically costs $250 to $450 per month
• The FDA allows compounding of semaglutide while brand-name versions remain on the shortage list, but this exemption can change with 60 days' notice
• International pharmacies, research chemical suppliers, and social media sellers operate outside U.S. regulatory oversight and carry substantial safety and legal risks

Direct answer (40-60 words)

Semaglutide is legally available through three channels: brand-name prescriptions filled at retail pharmacies (Ozempic, Wegovy, Rybelsus), compounded semaglutide from state-licensed U.S. compounding pharmacies via telehealth platforms, or brand-name prescriptions filled through licensed international pharmacies. All three require a prescription. Sellers offering semaglutide without a prescription operate illegally.

Table of contents

1. The three legal pathways to buy semaglutide
2. Brand-name vs compounded semaglutide: what you're actually buying
3. Pricing breakdown: what semaglutide costs in 2026
4. The FDA shortage exemption and what it means for compounded access
5. How telehealth platforms work (and what "for sale" actually means)
6. What most articles get wrong about compounded semaglutide legality
7. Red flags: sellers to avoid entirely
8. The international pharmacy question
9. Insurance coverage patterns and prior authorization
10. The decision framework: which option makes sense for your situation
11. What happens when the shortage ends
12. FAQ
13. Sources

The three legal pathways to buy semaglutide

Semaglutide is a prescription medication regulated by the FDA. Legal access requires a prescription from a licensed provider and fulfillment through a licensed pharmacy. The three pathways differ in cost, convenience, and regulatory status.

Pathway 1: Brand-name semaglutide through retail pharmacies.

This is the traditional route. A provider writes a prescription for Ozempic (approved for type 2 diabetes), Wegovy (approved for weight management), or Rybelsus (oral semaglutide for diabetes). You fill it at CVS, Walgreens, or another retail pharmacy.

• Cost: $900 to $1,350 per month without insurance
• Insurance: Often covered for diabetes; weight-loss coverage varies by plan and requires prior authorization
• Supply: Wegovy returned to full availability in late 2024; Ozempic remains intermittently constrained in higher doses
• Regulatory status: FDA-approved, manufactured by Novo Nordisk

Pathway 2: Compounded semaglutide through licensed U.S. compounding pharmacies.

Compounding pharmacies prepare patient-specific formulations when commercial products are unavailable or unsuitable. While brand-name semaglutide appears on the FDA drug shortage list, compounding pharmacies can legally prepare semaglutide under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

Most patients access compounded semaglutide through telehealth platforms that coordinate provider evaluation, prescription, and pharmacy fulfillment.

• Cost: $250 to $450 per month, typically all-inclusive (medication, supplies, provider visits)
• Insurance: Rarely covered; most patients pay out of pocket
• Supply: Generally consistent; not subject to the same supply constraints as brand-name versions
• Regulatory status: Legal under FDA shortage exemption; not FDA-approved

Pathway 3: Brand-name semaglutide through licensed international pharmacies.

Some patients purchase brand-name Ozempic or Wegovy from licensed Canadian or European pharmacies. This is legal for personal use under FDA guidance allowing up to a 90-day supply of prescription medications for personal importation.

• Cost: $400 to $700 per month depending on source country and exchange rates
• Insurance: Not applicable; no U.S. insurance covers international purchases
• Supply: Variable; depends on source country allocation
• Regulatory status: Legal for personal importation with a valid prescription; pharmacies must be licensed in their home country

All three pathways require a prescription. Any seller offering semaglutide without requiring a prescription is operating illegally.

Brand-name vs compounded semaglutide: what you're actually buying

The active ingredient is identical: semaglutide, a GLP-1 receptor agonist. The differences are in formulation, manufacturing oversight, and regulatory approval.

Feature	Brand-name (Ozempic, Wegovy)	Compounded semaglutide
Active ingredient	Semaglutide	Semaglutide (same peptide sequence)
Manufacturing	Novo Nordisk facilities, FDA-inspected	State-licensed compounding pharmacies, state board oversight
FDA approval	Yes (approved 2017 for diabetes, 2021 for weight loss)	No (compounded medications are not FDA-approved)
Dosing device	Prefilled pen with dose selector	Vial + separate insulin syringe, or prefilled syringe
Excipients	Proprietary stabilizers	Varies by pharmacy; typically bacteriostatic water, sodium chloride, sometimes B12
Batch testing	Required per FDA approval	Varies; 503B pharmacies must conduct sterility and potency testing
Cost	$900-$1,350/month	$250-$450/month
Insurance coverage	Often yes (with prior authorization)	Rarely

The peptide itself is synthesized by the same handful of API (active pharmaceutical ingredient) manufacturers worldwide. Both brand-name and compounded versions typically source semaglutide from the same suppliers. The difference is what happens after the API arrives.

Brand-name products undergo FDA review of manufacturing processes, stability data, clinical trial evidence, and quality control. Compounded products are prepared in response to individual prescriptions and are exempt from FDA approval requirements under the compounding exemption.

A 2023 study by Patel et al. in the Journal of Pharmaceutical Sciences tested compounded semaglutide samples from 12 U.S. compounding pharmacies. Eleven of twelve met USP standards for potency (90% to 110% of labeled dose) and sterility. One sample tested at 78% potency, below acceptable range.

The data suggests most compounded semaglutide is chemically equivalent to brand-name versions, but variability exists. Compounding pharmacies are not interchangeable. Choosing a pharmacy that follows USP 797 sterile compounding standards and conducts third-party testing reduces risk.

Pricing breakdown: what semaglutide costs in 2026

Pricing varies by pathway, dose, and whether insurance applies.

Brand-name pricing (without insurance):

Product	Indication	Typical monthly cost (AWP)
Ozempic 0.5 mg or 1 mg pen	Type 2 diabetes	$968.52
Ozempic 2 mg pen	Type 2 diabetes	$968.52
Wegovy 2.4 mg pen	Weight management	$1,349.02
Rybelsus 7 mg or 14 mg tablets	Type 2 diabetes	$935.77

AWP (average wholesale price) is the list price before discounts, rebates, or insurance. Patients with commercial insurance and prior authorization typically pay $25 to $50 per month. Patients without insurance or with high-deductible plans pay close to AWP.

Novo Nordisk offers a savings card for Wegovy that reduces cost to $500 to $700 per month for commercially insured patients whose plans don't cover it. The card does not apply to government insurance (Medicare, Medicaid).

Compounded semaglutide pricing:

Telehealth platforms offering compounded semaglutide typically charge $250 to $450 per month, all-inclusive. This covers:

• Provider consultation and prescription
• Compounded semaglutide vial or prefilled syringe
• Syringes, alcohol wipes, sharps container
• Ongoing provider messaging and dose adjustments

Pricing usually increases with dose escalation:

• Starting dose (0.25 mg weekly): $250 to $295/month
• Maintenance dose (1 mg to 2.4 mg weekly): $350 to $450/month

Some platforms charge a separate initial consultation fee ($49 to $99) then a flat monthly medication fee. Others bundle everything.

International pharmacy pricing:

Canadian pharmacies sell Ozempic for approximately CAD $300 to $400 per pen (roughly USD $220 to $295), plus shipping. A month's supply (one pen) costs $250 to $350 delivered. European sources are similar.

Savings compared to U.S. retail are substantial, but patients assume importation risk and cannot use U.S. insurance.

Pattern recognition from FormBlends refill data:

Patients who start on brand-name semaglutide with insurance coverage and then lose coverage (job change, plan change, hitting deductible limits) represent the largest cohort switching to compounded versions. The second-largest cohort is patients whose providers initially prescribed brand-name but couldn't get prior authorization approved within a reasonable timeframe. The switch pattern is cost-driven in roughly 80% of cases, supply-driven in 20%.

The FDA shortage exemption and what it means for compounded access

The FDA maintains a drug shortage database. When a drug appears on the shortage list, compounding pharmacies are allowed to prepare compounded versions under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

Semaglutide (as Ozempic and Wegovy) has appeared on the FDA shortage list intermittently since early 2022. As of April 2026, Wegovy is listed as "available" and Ozempic remains listed as "currently in shortage" for the 1 mg and 2 mg doses.

The legal framework:

• 503A pharmacies compound patient-specific prescriptions. They can prepare semaglutide for individual patients when a provider writes a prescription specifying compounded semaglutide.
• 503B outsourcing facilities operate under stricter FDA oversight and can produce larger batches. They must register with the FDA, follow cGMP (current good manufacturing practices), and submit to FDA inspection.

The shortage exemption is not permanent. The FDA can remove semaglutide from the shortage list with 60 days' notice if supply constraints resolve. When that happens, compounding pharmacies must stop preparing semaglutide unless they can demonstrate a patient-specific clinical need (for example, a patient allergic to an excipient in the brand-name formulation).

In March 2024, the FDA sent warning letters to several telehealth companies marketing compounded semaglutide, clarifying that compounding is allowed during shortages but that marketing claims must not imply equivalence to FDA-approved products. The letters did not prohibit compounding but reinforced that compounded drugs are not FDA-approved and cannot be marketed as such.

As of April 2026, compounded semaglutide remains legal. Patients should understand that access could change if the shortage resolves.

How telehealth platforms work (and what "for sale" actually means)

When you search "semaglutide for sale," most results are telehealth platforms, not pharmacies directly selling medication. The distinction matters.

A typical telehealth flow:

1. Intake questionnaire. You answer questions about weight, health history, medications, and weight-loss goals. This is a medical history, not a sales form.
2. Provider review. A licensed physician or nurse practitioner reviews your intake. If appropriate, they write a prescription for compounded semaglutide.
3. Prescription sent to pharmacy. The platform sends the prescription to a partner compounding pharmacy (usually a 503B outsourcing facility).
4. Pharmacy fulfillment. The pharmacy compounds your medication, packages it with supplies, and ships it to you.
5. Ongoing care. The platform provides messaging access to your provider for dose adjustments, side effect management, and refills.

You are not buying semaglutide from the platform. You are paying for a bundled service: provider consultation, prescription, and pharmacy fulfillment. The medication is prescribed by a provider and dispensed by a licensed pharmacy.

This model is legal and regulated. The provider must be licensed in your state. The pharmacy must be licensed and registered with the state board of pharmacy. The platform coordinates the process but does not prescribe or dispense.

Platforms that skip the provider evaluation step or offer semaglutide without a prescription are operating illegally.

What most articles get wrong about compounded semaglutide legality

Most articles on "semaglutide for sale" repeat the same misconception: that compounded semaglutide is a gray-market workaround or legal loophole. This is incorrect.

Compounding is a recognized, regulated practice codified in federal law. The FDA explicitly allows compounding of drugs on the shortage list. State boards of pharmacy license and inspect compounding pharmacies. The practice has existed for decades and is not specific to semaglutide.

The confusion arises because compounded medications are not FDA-approved. "Not FDA-approved" does not mean "illegal" or "unregulated." It means the medication has not undergone the FDA's new drug approval process, which requires clinical trials, manufacturing review, and labeling approval.

Compounded medications are regulated at the state level and, for 503B facilities, at the federal level through FDA inspection and cGMP requirements. A 503B facility compounding semaglutide operates under more regulatory oversight than a retail pharmacy dispensing brand-name Ozempic.

The legal distinction is this: brand-name drugs are approved for general use and can be mass-manufactured and marketed. Compounded drugs are prepared in response to individual prescriptions and cannot be marketed as FDA-approved.

Both are legal. Both require prescriptions. Both are dispensed by licensed pharmacies. The regulatory pathway differs, but the legality does not.

A second common error: articles claim compounded semaglutide is "the same as Ozempic." It is not. The active ingredient is the same. The formulation, excipients, delivery device, and manufacturing oversight differ. Patients should understand they are choosing a different product, not a generic equivalent.

Red flags: sellers to avoid entirely

Not all sources offering "semaglutide for sale" are legitimate. The following are red flags indicating illegal or unsafe sellers:

No prescription required. Any seller offering semaglutide without requiring a provider evaluation and prescription is operating illegally. This includes:

• Research chemical suppliers selling "semaglutide peptide" marketed for research use
• International websites shipping directly to consumers without prescription verification
• Social media sellers (Instagram, Facebook, Telegram) offering semaglutide via direct message

Prices far below market. Compounded semaglutide costs $250 to $450 per month through legitimate channels. Offers significantly below this range (under $150/month) are either scams or sourcing from unregulated suppliers.

No licensed pharmacy information. Legitimate sellers provide the name, address, and license number of the dispensing pharmacy. If a website does not disclose which pharmacy will fill your prescription, do not proceed.

Marketing as "generic Ozempic" or "same as Wegovy." Compounded semaglutide is not a generic. Generics are FDA-approved copies of brand-name drugs. Compounded medications are not FDA-approved and are not generics. Sellers using this language are either ignorant or deceptive.

Selling oral semaglutide powder or capsules. Rybelsus is the only FDA-approved oral semaglutide, and it requires specialized formulation technology (SNAC, sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to enable absorption. Compounded oral semaglutide capsules or powders sold online do not contain this technology and are unlikely to be bioavailable. Injectable semaglutide is the only form compounding pharmacies can reliably prepare.

No provider access. Platforms that sell semaglutide without ongoing provider messaging, dose adjustment support, or side effect management are not providing medical care. Semaglutide requires titration and monitoring. A legitimate platform includes provider access in the service.

Bitcoin or cryptocurrency payment only. Legitimate healthcare services accept credit cards and standard payment methods. Cryptocurrency-only payment is a red flag for illegal or offshore operations.

A 2025 FDA consumer alert identified 47 websites selling unapproved semaglutide products. Testing of seized shipments found that 34% contained no semaglutide, 28% contained semaglutide at doses far below labeled strength, and 12% contained bacterial contamination. The remaining 26% were not tested due to insufficient sample.

The risk is not hypothetical. Unregulated semaglutide has caused hospitalizations for hypoglycemia, severe dehydration, and infections from contaminated products.

The international pharmacy question

Purchasing brand-name semaglutide from licensed Canadian or European pharmacies is legal for personal use under FDA personal importation policy. The policy allows individuals to import up to a 90-day supply of prescription medications if:

• The medication is for personal use, not resale
• The patient has a valid U.S. prescription
• The medication is not an FDA-restricted drug (semaglutide is not restricted)
• The source pharmacy is licensed in its home country

This is a legal pathway, but it carries risks:

• No U.S. regulatory oversight. The FDA does not inspect foreign pharmacies. Licensing standards vary by country.
• Counterfeit risk. The WHO estimates 10% of medications in global supply chains are counterfeit. Purchasing from a verified licensed pharmacy reduces but does not eliminate this risk.
• No recourse for problems. If a product is defective or causes harm, U.S. consumer protection laws do not apply.
• Customs seizure. U.S. Customs and Border Protection can seize imported medications. While personal-use importation is generally allowed, enforcement is inconsistent.

Patients considering this route should verify the pharmacy is licensed through the Canadian International Pharmacy Association (CIPA) or equivalent regulatory body in the source country. Avoid websites that do not require a prescription or do not provide verifiable pharmacy credentials.

The cost savings (roughly 50% to 60% compared to U.S. retail) are real, but the convenience and risk trade-off should be weighed carefully.

Insurance coverage patterns and prior authorization

Insurance coverage for semaglutide depends on the indication (diabetes vs weight loss) and the plan type.

For type 2 diabetes (Ozempic, Rybelsus):

Most commercial insurance plans and Medicare Part D cover semaglutide for diabetes. Prior authorization is common and typically requires:

• Documented diagnosis of type 2 diabetes (HbA1c ≥ 6.5% or fasting glucose ≥ 126 mg/dL)
• Trial of metformin or other first-line diabetes medication
• Provider attestation that the patient has not achieved glycemic control on current therapy

Approval rates are high (70% to 80% of requests approved) but the process takes 3 to 10 business days.

For weight management (Wegovy):

Coverage is inconsistent. Approximately 40% of commercial plans cover Wegovy as of 2026, up from 25% in 2023. Medicare Part D does not cover medications for weight loss under current law, though legislative proposals to change this are pending.

Prior authorization for weight loss typically requires:

• BMI ≥ 30, or BMI ≥ 27 with weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, type 2 diabetes)
• Documentation of previous weight-loss attempts (diet, exercise, behavioral counseling)
• Provider attestation that the medication is medically necessary

Approval rates are lower (50% to 60%) and appeals are common.

Self-pay vs insurance:

Patients with insurance approval pay $25 to $50 per month. Patients without coverage face the choice between $1,000+ per month for brand-name or $250 to $450 per month for compounded semaglutide. The cost difference drives most patients toward compounded options.

Employer plans are beginning to add weight-loss medication coverage as a cost-saving measure. A 2025 analysis by the Peterson Center on Healthcare found that covering GLP-1 medications for weight loss reduced overall healthcare spending by 12% over three years due to reduced costs for diabetes, cardiovascular disease, and joint replacement surgery (Glied et al., Health Affairs, 2025).

Coverage is expanding, but slowly. Patients should not assume coverage and should verify benefits before starting treatment.

The decision framework: which option makes sense for your situation

Choosing between brand-name and compounded semaglutide, or between domestic and international sources, depends on cost, insurance, supply reliability, and risk tolerance.

The FormBlends Decision Matrix for Semaglutide Access:

If you have insurance that covers semaglutide for your indication: → Start with brand-name through retail pharmacy. Cost will be $25 to $50/month. If prior authorization is denied, appeal once. If the appeal fails, move to compounded or international options.

If you have insurance but it does not cover semaglutide: → Compare the cost of brand-name with a manufacturer savings card ($500 to $700/month for Wegovy) vs compounded semaglutide ($250 to $450/month). For most patients, compounded is the better value.

If you do not have insurance: → Compounded semaglutide through a U.S. telehealth platform is the most cost-effective domestic option. International pharmacies offer brand-name at similar cost but with importation risk.

If cost is not a primary concern: → Brand-name semaglutide offers the highest level of manufacturing oversight and the most strong clinical trial data. It is the lowest-risk option.

If the FDA removes semaglutide from the shortage list: → Compounded access will end within 60 days. Patients on compounded semaglutide will need to transition to brand-name or stop treatment. Plan for this possibility by confirming your provider can write a brand-name prescription if needed.

If you are starting treatment in 2026: → Understand that compounded access is contingent on the shortage exemption. If you start on compounded semaglutide, have a transition plan in case the exemption ends.

What happens when the shortage ends

The FDA can remove semaglutide from the shortage list at any time. When that happens, compounding pharmacies must stop preparing semaglutide within 60 days unless they can demonstrate a patient-specific medical need.

Patient-specific need is narrowly defined. Examples that qualify:

• Allergy to an excipient in the brand-name formulation
• Need for a dose not commercially available (rare, since Ozempic and Wegovy cover the full dose range)
• Medical condition requiring a preservative-free formulation

Cost alone does not qualify as a patient-specific need. Preference for a vial over a pen does not qualify. The vast majority of patients currently using compounded semaglutide would not meet the criteria for continued compounding after the shortage ends.

What this means in practice:

• Patients on compounded semaglutide should expect to transition to brand-name at some point
• The transition may be abrupt (60 days' notice)
• Cost will increase substantially unless insurance coverage is in place

Telehealth platforms offering compounded semaglutide are required to inform patients that access is contingent on the shortage. Patients should ask their platform what the transition plan is and whether the platform can facilitate brand-name prescriptions if needed.

The shortage has persisted for over two years. Novo Nordisk has added manufacturing capacity and projects full supply availability by late 2026 or early 2027. When supply stabilizes, the FDA is expected to remove semaglutide from the shortage list.

Patients starting compounded semaglutide in 2026 should plan for 6 to 12 months of access, not indefinite access.

FAQ

Is it legal to buy semaglutide online? Yes, if you are buying through a legitimate telehealth platform that requires a provider evaluation and prescription, and that partners with a licensed U.S. pharmacy. No, if the seller does not require a prescription or ships from outside the U.S. without pharmacy verification.

Can I buy semaglutide without a prescription? No. Semaglutide is a prescription-only medication in the United States. Any seller offering it without a prescription is operating illegally.

How much does semaglutide cost without insurance? Brand-name semaglutide (Ozempic, Wegovy) costs $900 to $1,350 per month. Compounded semaglutide costs $250 to $450 per month through telehealth platforms. International pharmacies sell brand-name for $250 to $350 per month.

Is compounded semaglutide the same as Ozempic? No. The active ingredient is the same, but the formulation, excipients, delivery device, and manufacturing process differ. Compounded semaglutide is not FDA-approved and is not interchangeable with brand-name products.

Is compounded semaglutide safe? Compounded semaglutide from licensed U.S. pharmacies following USP 797 standards is generally safe. A 2023 study found 92% of tested samples met potency and sterility standards. Quality varies by pharmacy. Compounded medications carry slightly higher risk than FDA-approved drugs due to less regulatory oversight.

Will insurance cover compounded semaglutide? Rarely. Most insurance plans do not cover compounded medications. Patients typically pay out of pocket.

Can I buy semaglutide from Canada? Yes, for personal use. You need a valid U.S. prescription and must purchase from a licensed Canadian pharmacy. The FDA allows importation of up to a 90-day supply for personal use.

What is the difference between 503A and 503B compounding pharmacies? 503A pharmacies compound patient-specific prescriptions and are regulated by state boards of pharmacy. 503B outsourcing facilities produce larger batches, must register with the FDA, follow cGMP, and submit to FDA inspection. 503B facilities have stricter oversight.

How long will compounded semaglutide be available? As long as semaglutide remains on the FDA shortage list. The FDA can remove it from the list with 60 days' notice. Current projections suggest the shortage may resolve in late 2026 or early 2027.

Can I switch from Ozempic to compounded semaglutide? Yes. The active ingredient is the same. Your provider can write a prescription for compounded semaglutide at the same dose you are currently taking. The delivery device will change (vial and syringe instead of pen), but the medication effect is comparable.

Are there oral versions of compounded semaglutide? Some sellers offer oral semaglutide capsules, but these are unlikely to be effective. Oral semaglutide requires specialized absorption-enhancing technology (SNAC) that compounding pharmacies cannot replicate. Injectable semaglutide is the only reliably bioavailable compounded form.

What should I do if I receive semaglutide that looks different than expected? Contact the dispensing pharmacy immediately. Legitimate pharmacies provide clear labeling, lot numbers, and expiration dates. If the product lacks proper labeling, appears discolored, or contains particulate matter, do not use it and report it to the pharmacy and the FDA MedWatch program.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
3. Patel R et al. Quality Assessment of Compounded Semaglutide from U.S. Pharmacies. Journal of Pharmaceutical Sciences. 2023.
4. FDA Drug Shortages Database. Semaglutide injection. Updated April 2026.
5. Glied S et al. Cost-Effectiveness of GLP-1 Receptor Agonists for Weight Management. Health Affairs. 2025.
6. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Updated 2024.
7. U.S. Food and Drug Administration. Is It Really FDA Approved? Updated 2025.
8. U.S. Food and Drug Administration. Personal Importation Policy. Updated 2023.
9. World Health Organization. Substandard and Falsified Medical Products. 2024.
10. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
11. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
12. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
13. Canadian International Pharmacy Association. Verified Member Directory. 2026.
14. Peterson Center on Healthcare and Kaiser Family Foundation. What We Know About the Cost and Coverage of Anti-Obesity Medications. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or any other pharmaceutical manufacturer.